We are committed to innovation and constantly pushing the boundaries of science


MedImmune employees globally


Biologics in research and development


Publications in 2014

Our capabilities

Personalised medicine at MedImmune

Committed to driving innovation, no matter where it hides

Commitment to science

Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy

Published: 20 May 2015

Area: Inflammation and Autoimmunity 

AstraZeneca/MedImmune author: Tomas Mustelin

IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk

Published: 16 March 2015

Area: Respiratory

AstraZeneca/MedImmune author:  Richard May (MedImmune)  

Low-frequency coding variants at 6p22.2-6p21.31 and 20q11.21 are associated with lung cancer risk in Chinese populations

Published: 7 May 2015

Area: Oncology

AstraZeneca/MedImmune author: Brandon Higgs